{"organizations": [], "uuid": "119313dcc9f0dadb768ffb93834a2b6a4bc8fdb8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/markets/us", "section_title": "US Stock Market News - Dow Jones, Nasdaq, S&amp;P 500 | Reuters.com", "url": "https://www.reuters.com/article/brief-ziopharm-oncology-to-initiate-pivo/brief-ziopharm-oncology-to-initiate-pivotal-trial-of-cancer-treatment-in-second-half-of-2018-idUSASB0C0BJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Ziopharm Oncology To Initiate Pivotal Trial Of Cancer Treatment in Second Half of 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.498, "site_type": "news", "published": "2018-01-09T20:50:00.000+02:00", "replies_count": 0, "uuid": "119313dcc9f0dadb768ffb93834a2b6a4bc8fdb8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ziopharm-oncology-to-initiate-pivo/brief-ziopharm-oncology-to-initiate-pivotal-trial-of-cancer-treatment-in-second-half-of-2018-idUSASB0C0BJ", "ord_in_thread": 0, "title": "BRIEF-Ziopharm Oncology To Initiate Pivotal Trial Of Cancer Treatment in Second Half of 2018", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ziopharm oncology inc", "sentiment": "negative"}, {"name": "j.p. morgan healthcare", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 50 PM / Updated 8 minutes ago BRIEF-Ziopharm Oncology To Initiate Pivotal Trial Of Cancer Treatment in Second Half of 2018 Reuters Staff \nJan 9 (Reuters) - Ziopharm Oncology Inc: \n* ZIOPHARM ONCOLOGY PROVIDES UPDATE ON STANDOUT TECHNOLOGIES DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE \n* ZIOPHARM ONCOLOGY - UPDATED GUIDANCE ON PLANNED PIVOTAL TRIAL TO EVALUATE CONTROLLED IL-12 AND ANNOUNCED THAT IT WILL INITIATE IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-09T20:50:00.000+02:00", "crawled": "2018-01-09T15:01:56.010+02:00", "highlightTitle": ""}